These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20923295)

  • 1. Acute myeloid leukemia diagnosis in the 21st century.
    Betz BL; Hess JL
    Arch Pathol Lab Med; 2010 Oct; 134(10):1427-33. PubMed ID: 20923295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of acute myeloid leukemia.
    Döhner K; Döhner H
    Haematologica; 2008 Jul; 93(7):976-82. PubMed ID: 18591623
    [No Abstract]   [Full Text] [Related]  

  • 3. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.
    Jung J; Cho BS; Kim HJ; Han E; Jang W; Han K; Lee JW; Chung NG; Cho B; Kim M; Kim Y
    Ann Lab Med; 2019 May; 39(3):311-316. PubMed ID: 30623623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acute myeloid leukemia].
    Watanabe R
    Rinsho Ketsueki; 2009 Mar; 50(3):154-9. PubMed ID: 19352081
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinically useful prognostic factors in acute myeloid leukemia.
    Ferrara F; Palmieri S; Leoni F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):181-93. PubMed ID: 17996460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
    Luquet I; Bidet A; Cuccuini W; Lafage-Pochitaloff M; Mozziconacci MJ; Terré C
    Ann Biol Clin (Paris); 2016 Oct; 74(5):535-546. PubMed ID: 27545007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
    Marcucci G; Haferlach T; Döhner H
    J Clin Oncol; 2011 Feb; 29(5):475-86. PubMed ID: 21220609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostics, classification and prognostic criteria of acute myeloid leukemia].
    Heilmeier B; Buske C; Spiekermann K; Bohlander S; Feuring-Buske M; Hiddemann W; Braess J
    Med Klin (Munich); 2007 Apr; 102(4):296-308. PubMed ID: 17426933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
    Han TJ; Xu XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1063-8. PubMed ID: 20723330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
    Martelli MP; Sportoletti P; Tiacci E; Martelli MF; Falini B
    Blood Rev; 2013 Jan; 27(1):13-22. PubMed ID: 23261068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors of acute myeloid leukemia].
    Inokuchi K
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():389-93. PubMed ID: 23133988
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype.
    Bacher U; Haferlach T; Alpermann T; Kern W; Schnittger S; Haferlach C
    Leukemia; 2013 Feb; 27(2):496-500. PubMed ID: 22858909
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
    Gaidzik V; Döhner K
    Semin Oncol; 2008 Aug; 35(4):346-55. PubMed ID: 18692685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in AML in relation to (ab)normal karyotype.
    Stone RM
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):523-8. PubMed ID: 19959103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
    Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
    Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
    Zhang Q; Bai S; Vance GH
    Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.